Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable) announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight L …

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable) announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors.

Toronto-based Winterlight Labs Inc. is developing a proprietary Artificial Intelligence (AI) technology that melds computational linguistics, cognitive neuroscience, and machine learning to help healthcare professionals assess and analyse patients’ cognitive health – including memory, thinking and reasoning – from vocal markers captured in short snippets of speech on a tablet computer. Read more here.